TIDMPOLX

RNS Number : 3897U

Polarean Imaging PLC

01 April 2021

Polarean Imaging Plc

("Polarean" or the "Company")

Total Voting Rights

Polarean Imaging plc (AIM: POLX), the medical--imaging technology company, with a proprietary drug--device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 166,117,636 ordinary shares of GBP0.00037 each.

The total issued share capital of the Company consists of 166,117,636 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
 Polarean Imaging plc                                        www.polarean.com / www.polarean-ir.com 
 Richard Hullihen, Chief Executive                                                  Via Walbrook PR 
  Officer 
  Jonathan Allis, Chairman 
 
 Stifel Nicolaus Europe Limited (NOMAD and 
  Sole Corporate Broker)                                                        +44 (0)20 7710 7600 
 Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare 
  Investment Banking) 
 Nick Adams / Fred Walsh (Corporate 
  Broking) 
 
 Walbrook PR                                    Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
 Paul McManus / Anna Dunphy                                  Mob: +44 (0)7980 541 893 / +44 (0)7876 
                                                                                            741 001

About Polarean ( www.polarean.com )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREASLFELNFEFA

(END) Dow Jones Newswires

April 01, 2021 11:52 ET (15:52 GMT)

Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Polarean Imaging Charts.
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Polarean Imaging Charts.